Boston Scientific Corporation (BSX)

Basic

  • Market Cap

    $80.5B

  • EV

    $89.09B

  • Shares Out

    1,464.98M

  • Revenue

    $13.76B

  • Employees

    45,000

Margins

  • Gross

    69.06%

  • EBITDA

    25.46%

  • Operating

    16.91%

  • Pre-Tax

    13.63%

  • Net

    8.93%

  • FCF

    12.34%

Returns (5Yr Avg)

  • ROA

    3.86%

  • ROE

    14.57%

  • ROCE

    7.62%

  • ROIC

    15.13%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $60.22

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $9.52

  • Earnings (Dil)

    $0.82

  • FCF

    $1.17

  • Book Value

    $12.89

Growth (CAGR)

  • Rev 3Yr

    10.82%

  • Rev 5Yr

    7.3%

  • Rev 10Yr

    6.8%

  • Dil EPS 3Yr

    -31.94%

  • Dil EPS 5Yr

    11.21%

  • Dil EPS 10Yr

    20.77%

  • Rev Fwd 2Yr

    9.84%

  • EBITDA Fwd 2Yr

    11.72%

  • EPS Fwd 2Yr

    14.41%

  • EPS LT Growth Est

    12.2%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

9,823.0

10,735.0

9,913.0

11,888.0

12,682.0

13,757.0

Total Revenues % Chg.

8.6%

9.3%

-7.7%

19.9%

6.7%

9.5%

Cost of Goods Sold, Total

2,830.0

3,103.0

3,242.0

3,760.0

4,003.0

4,257.0

Gross Profit

6,993.0

7,632.0

6,671.0

8,128.0

8,679.0

9,500.0

Selling General & Admin Expenses, Total

3,557.0

3,928.0

3,787.0

4,359.0

4,520.0

4,974.0

R&D Expenses

1,113.0

1,174.0

1,143.0

1,204.0

1,323.0

1,381.0

Amortization of Goodwill and Intangible Assets

599.0

699.0

789.0

741.0

803.0

819.0

Other Operating Expenses, Total

5,269.0

5,801.0

5,719.0

6,304.0

6,646.0

7,174.0

Operating Income

1,724.0

1,831.0

952.0

1,824.0

2,033.0

2,326.0

Interest Expense, Total

-241.0

-473.0

-361.0

-341.0

-470.0

-264.0

Interest And Investment Income

3.0

30.0

3.0

4.0

10.0

10.0

Net Interest Expenses

-238.0

-443.0

-358.0

-337.0

-460.0

-254.0

Currency Exchange Gains (Loss)

11.0

-35.0

-32.0

-27.0

-31.0

-16.0

Other Non Operating Income (Expenses)

-12.0

1.0

6.0

-7.0

-14.0

—

EBT, Excl. Unusual Items

1,485.0

1,354.0

568.0

1,453.0

1,528.0

2,056.0

Restructuring Charges

-95.0

-83.0

-179.0

-40.0

-24.0

-57.0

Merger & Related Restructuring Charges

-6.0

-369.0

—

—

—

—

Impairment of Goodwill

—

—

-73.0

—

—

—

Gain (Loss) On Sale Of Investments

155.0

-30.0

383.0

250.0

-1.0

-14.0

Gain (Loss) On Sale Of Assets

—

—

—

78.0

-22.0

-22.0

Asset Writedown

-35.0

-105.0

-452.0

-370.0

-132.0

-58.0

Legal Settlements

-103.0

-115.0

-278.0

-430.0

-173.0

-20.0

Other Unusual Items

21.0

35.0

-49.0

136.0

-35.0

-10.0

EBT, Incl. Unusual Items

1,422.0

687.0

-80.0

1,077.0

1,141.0

1,875.0

Income Tax Expense

-249.0

-4,013.0

2.0

36.0

443.0

647.0

Earnings From Continuing Operations

1,671.0

4,700.0

-82.0

1,041.0

698.0

1,228.0

Net Income

1,671.0

4,700.0

-82.0

1,041.0

698.0

1,228.0

Preferred Dividend and Other Adjustments

—

—

33.0

56.0

56.0

37.0

Net Income to Common Incl Extra Items

1,671.0

4,700.0

-115.0

985.0

642.0

1,191.0

Net Income to Common Excl. Extra Items

1,671.0

4,700.0

-115.0

985.0

642.0

1,191.0

Total Shares Outstanding

1,384.6

1,394.9

1,416.6

1,425.5

1,433.3

1,464.9

Weighted Avg. Shares Outstanding

1,381.0

1,391.5

1,416.7

1,422.3

1,430.5

1,444.8

Weighted Avg. Shares Outstanding Dil

1,401.4

1,410.6

1,416.7

1,433.8

1,439.7

1,455.0

EPS

1.2

3.4

-0.1

0.7

0.4

0.8

EPS Diluted

1.2

3.3

-0.1

0.7

0.4

0.8

EBITDA

2,618.0

2,842.0

2,075.0

2,917.0

3,169.0

3,503.0